только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 4 / 10
Страница 1 / 1

Список литературы

  1. Korgavkar K., Xiong M., Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatology. 2013; 149 (11): 1295–1299. DOI:10.1001/jamadermatol.2013.5526
  2. Zwierzina H., Suciu S., Loeffler-Ragg J. et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia. 2005;19 (11):1929–1933. DOI:10.1038/sj.leu.2403934.
  3. Keehn C.A., Belongie I.P., Shistik G. et al. The diagnosis, staging, and treatment options for mycosis fungoides. Cancer Control. 2007; 14 (2): 102–111. DOI:10.1177/107327480701400203.
  4. Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37 (1): 2–10. DOI:10.12788/j.sder.2018.002.
  5. Willemze R. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37 (1):11–17. DOI:10.12788/j.sder.2018.004.
  6. Olsen E., Vonderheid E., Pimpinelli N. et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 15; 110 (6): 1713–1722. DOI:10.1182/blood-2007-03-055749.
  7. Horwitz S.M., Olsen E.A., Duvic M. et al. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008; 6 (4): 436–442. doi: 10.6004/jnccn.2008.0033
  8. Delfau-Larue M.H., Laroche L., Wechsler J. et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000; 96 (9): 2987–2992. DOI:10.1182/blood.v96.9.2987
  9. Ponti R., Quaglino P., Novelli M. et al. T-cell receptor γ gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: Correlation with clinical, histological and immunophenotypical findings. Br J Dermatol. 2005; 153 (3): 565–573. DOI:10.1111/j.1365-2133.2005.06649.x
  10. Kirsch I.R., Watanabe R., O’Malley J.T. et al. TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med. 2015 Oct 7;7 (308): 308ra158. DOI:10.1126/scitranslmed.aaa9122
  11. Matos T.R., de Rie M.A., Teunissen M.B. Research techniques made simple: High-throughput sequencing of the T-cell receptor. J Invest Dermatol. 2017; 137 (6): e131–e138. DOI:10.1016/j.jid.2017.04.001
  12. Scherer F., Kurtz D.M., Diehn M., Alizadeh A.A. High-throughput sequencing for noninvasive disease detection in hematologic malignancies. Blood. 2017; 130 (4): 440–452. DOI:10.1182/blood-2017-03-735639
  13. Jawed S.I., Myskowski P.L., Horwitz S. et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014; 70 (2): 205.e1–16 DOI:10.1016/j.jaad.2013.07.049
  14. Rea B., Haun P., Emerson R. et al. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. J Clin Pathol. 2018; 71 (9): 814–820. DOI:10.1136/jclinpath-2018-205004
  15. Ferner R.E. Adverse drug reactions in dermatology. Clin Exp Dermatol. 2015; 40 (2): 105–109. DOI:10.1111/ced.12572
  16. Federico M., Bellei M., Marcheselli L. et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. 2018; 181 (6): 760–769. DOI:10.1111/bjh.15258
  17. Huang D.Y., Hu Y.F., Wei N., et al. Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chin Med J (Engl). 2019; 132 (3): 294–301. DOI:10.1097/CM9.0000000000000088
  18. Olsen E.A. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003; 16 (4): 311–321. DOI:10.1111/j.1396-0296.2003.01643.x
  19. Campbell J.M., Bateman E., Stephenson M.D. et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother Pharmacol. 2016; 78 (1): 27–39. DOI:10.1007/s00280-016-3043-5
  20. Mann B.S., Johnson J.R., Cohen M.H. et al. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T‐cell lymphoma. Oncologist. 2007; 12 (10): 1247–1252. DOI:10.1634/theoncologist.12-10-1247
  21. Prince H.M., Kim Y.H., Horwitz S. et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390 (10094): 555–566. DOI:10.1016/S0140-6736(17)31266-7
  22. Gerami P., Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic mycosis fungoides. Am J Surg Pathol. 2007; 31 (9): 1430–1438. DOI:10.1097/PAS.0b013e3180439bdc
  23. Alpdogan O., Kartan S., Johnson W. et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol. 2019; 8 (1): 10. DOI:10.21037/cco.2019.01.02
  24. Swerdlow S.H., Campo E., Pileri S.A. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127 (20): 2375–2390. DOI:10.1182/blood-2016-01-643569
  25. Guitart J., Kennedy J., Ronan S. et al. Histologic criteria for the diagnosis of mycosis fungoides: Proposal for a grading system to standardize pathology reporting. J Cutan Pathol. 2001; 28 (4): 174–183. DOI:10.1034/j.1600-0560.2001.028004174.x
  26. Raghavan S.S., Kim J. Histopathologic approach to epidermotropic lymphocytic infiltrates. Semin Cutan Med Surg. 2018; 37 (1): 56–60. DOI:10.12788/j.sder.2018.003
  27. Charli-Joseph Y., Toussaint-Caire S., Lome-Maldonado C. et al. Approach to dermal-based lymphoid infiltrates and proliferations. Semin Cutan Med Surg. 2018; 37 (1): 61–74. DOI:10.12788/j.sder.2018.015
  28. Kempf W., Mitteldorf C. Pathologic diagnosis of cutaneous lymphomas. Dermatol Clin. 2015; 33 (4): 655–681. DOI: 10.1016/j.det.2015.05.002
  29. Vandergriff T., Nezafati K.A., Susa J. et al. Defining early mycosis fungoides: Validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas. J Cutan Pathol. 2015; 42 (5): 318–328. DOI:10.1111/cup.12470
  30. Pimpinelli N., Olsen E.A., Santucci M. et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005; 53 (6): 1053–1063. DOI:10.1016/j.jaad.2005.08.057
  31. Kash N., Massone C., Fink-Puches R. et al. Phenotypic variation in different lesions of mycosis fungoides biopsied within a short period of time from the same patient. Am J Dermatopathol. 2016; 38 (7): 541–545. DOI:10.1097/DAD.0000000000000493
  32. De Masson A., Battistella M., Vignon-Pennamen M.D. et al. Syringotropic mycosis fungoides: Clinical and histologic features, response to treatment, and outcome in 19 patients. J Am Acad Dermatol. 2014; 71 (5): 926–934. DOI:10.1016/j.jaad.2014.06.033
  33. Zhang Y., Wang Y., Yu R. et al. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol. 2012; 132 (6): 1698–1706. DOI:10.1038/jid.2012.13
  34. Haghighi B., Smoller B.R., LeBoit P.E. et al. Pagetoid reticulosis (Woringer-Kolopp disease): An immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000; 13 (5): 502–510. DOI:10.1038/modpathol.3880088
  35. Haththotuwa R., Zilinskiene L., Oliff J. et al. Biopsy correlation of surface area vs. single‐axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome. Br J Dermatol. 2017; 177 (3): 877–878. DOI:10.1111/bjd.15266
  36. Salhany K.E., Greer J.P., Cousar J.B. et al. Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases. Am J Clin Pathol. 1989; 92 (6): 747–754. DOI:10.1093/ajcp/92.6.747
  37. Horna P., Wang S.A., Wolniak K.L. et al. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics. Cytometry B Clin Cytom. 2021; 100 (2): 142–155. DOI:10.1002/cyto.b.21878
  38. Kim E.J., Hess S., Richardson S.K. et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005; 115 (4): 798–812. DOI:10.1172/jci24826
  39. Zackheim H.S. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003; 16 (4): 283–287. DOI:10.1111/j.1396-0296.2003.01639.x
  40. Diederen P.V., Van Weelden H., Sanders C.J. et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective study. J Am Acad Dermatol. 2003; 48 (2): 215–219. DOI:10.1067/mjd.2003.80
  41. Gathers R.C., Scherschun L., Malick F. et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002; 47 (2): 191–197. DOI:10.1067/mjd.2002.120911
  42. Ponte P., Serrão V., Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatology Venereol. 2010; 24 (6): 716–721. DOI:10.1111/j.1468-3083.2009.03500.x
  43. Кубанов А.А., Карамова А.Э., Знаменская Л.Ф. и др. Фототерапия грибовидного микоза. Онкогематология. 2019; 14 (4): 39–47.
  44. Querfeld C., Rosen S.T., Kuzel T.M. et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol. 2005; 141 (3): 305–311. DOI:10.1001/archderm.141.3.305
  45. Hoppe R.T. Mycosis fungoides: radiation therapy. Dermatol Ther. 2003; 16 (4): 347–354. DOI:10.1111/j.1396-0296.2003.01647.x
  46. Hymes K.B. Choices in the treatment of cutaneous T-cell lymphoma. Oncology (Williston Park). 2007; 21 (2 Suppl. 1): 18–23.
  47. Specht L., Dabaja B., Illidge T. et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015; 92 (1): 32–39. DOI:10.1016/j.ijrobp.2015.01.008
  48. Zackheim H.S., Kashani-Sabet M., McMillan A. Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49 (5): 873–878. DOI:10.1016/S0190-9622(03)01591-3
  49. Prince H.M., Whittaker S., Hoppe R.T. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114 (20): 4337–4353. DOI:10.1182/blood-2009-07-202895
  50. Duvic M., Talpur R., Ni X. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109 (1): 31–39. DOI:10.1182/blood-2006-06-025999
  51. Olsen E.A., Kim Y.H., Kuzel T.M. et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25 (21): 3109–3115. DOI:10.1200/JCO.2006.10.2434
  52. Duvic M., Olsen E., Breneman D. et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009; 9 (6): 412–416. DOI:10.3816/CLM.2009.n.082
  53. Zinzani P.L., Baliva G., Magagnoli M. et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients. J Clin Oncol. 2000; 18 (13): 2603–2606. DOI:10.1200/JCO.2000.18.13.2603
  54. Kim Y.H., Tavallaee M., Sundram U. et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project. J Clin Oncol. 2015; 33 (32): 3750–3758. DOI:10.1200/JCO.2014.60.3969
  55. Chung C.G., Poligone B. Other chemotherapeutic agents in cutaneous T-cell lymphoma. Dermatol Clin. 2015; 33 (4): 787–805. DOI:10.1016/j.det.2015.05.012
  56. Purnak S., Azar J., Mark L.A. Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis. Dermatol Ther. 2018; 31 (2): e12586. DOI:10.1111/dth.12586
  57. Damaj G., Gressin R., Bouabdallah K. et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY trial. J Clin Oncol. 2013; 31 (1): 104–110. DOI:10.1200/JCO.2012.43.7285
  58. Zinzani P.L., Musuraca G., Toni M. et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25 (27): 4293–4297. DOI:10.1200/JCO.2007.11.4207
  59. Fisher R.I., Gaynor E.R., Dahlberg S. et al. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin’s Lymphoma. N Engl J Med. 1993; 328 (14): 1002–1006. DOI:10.1056/nejm199304083281404
  60. Trautinger F., Eder J., Assaf C. et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer. 2017 May; 77: 57–74. DOI:10.1016/j.ejca.2017.02.027
  61. Grozea P.N., Jones S.E., McKelvey E.M. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep. 1979; 63 (4): 647–653.
  62. Kim S.J., Yoon D.H., Kang H.J. et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012; 48 (17): 3223–3231. DOI:10.1016/j.ejca.2012.06.003
  63. Wu P.A., Kim Y.H., Lavori P.W. et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant. 2009; 15 (8): 982–990. DOI:10.1016/j.bbmt.2009.04.017
  64. Duarte R.F., Canals C., Onida F. et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: A retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010; 28 (29): 4492–4499. DOI:10.1200/JCO.2010.29.3241
  65. Serrano L., Martinez-Escala M.E., Zhou X.A. et al. Pruritus in cutaneous T-cell lymphoma and its management. Dermatol Clin. 2018; 36 (3): 245–258. DOI:10.1016/j.det.2018.02.011
  66. Лезвинская Е.М., Вавилов А.М. Лимфопролиферативные опухоли кожи: руководство для врачей. М.: Практическая медицина; 2010, 366 с.
  67. Wolff J.M., Zitelli J.A., Rabin B.S. et al. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol. 1985; 13 (4): 604–612. doi: 10.1016/s0190-9622(85)70205-8
  68. Tan E., Tay Y.K., Giam Y.C. Profile and outcome of childhood mycosis fungoides in Singapore. Pediatr Dermatol. 2000; 17 (5): 352–356. doi: 10.1046/j.1525-1470.2000.017005352.x
  69. Geller S., Myskowski P.L. Topical clobetasol propionate treatment and cutaneous adverse effects in patients with early-stage mycosis fungoides: an observational study. Cutis. 2020; 105 (5): E27–E32
  70. Patraquim C., Gomes M.M., Garcez C. et al. Childhood hypopigmented mycosis fungoides: A rare diagnosis. Case Rep Pediatr. 2016; 2016: 8564389. doi: 10.1155/2016/8564389
  71. Itoh K., Ohtsu T., Fukuda H. et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin"s lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol. 2002; 13 (9): 1347–1355. doi: 10.1093/annonc/mdf287
  72. Foss F.M., Sjak-Shie N., Goy A. et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013; 54 (7): 1373–1379. doi: 10.3109/10428194.2012.742521
  73. Aparna C, Renuka IV, Rajani M, Sailabala G, Annapurna P. Primary extranodal lymphomas - spectrum of distribution and morphology with immunophenotyping: A 3-year institutional study. Med J DY Patil Univ 2015; 8: 138–143. DOI:10.4103/0975-2870.153137
  74. Hooper M., Zhang Y., Taylor E. et al. Practice patterns in children, adolescents, and young adults with mycosis fungoides: Single institution study. J Clin Oncol. 2021; 39 (15 Suppl.). Meeting Abstract. 2021 ASCO Annual Meeting I: e19553. DOI: 10.1200/JCO.2021.39.15_suppl.e19553
  75. Мякова Н.В., Абрамов Д.С., Пшонкин А.В., Коновалов Д.М. Редкий случай грибовидного микоза у детей. Собственное наблюдение и обзор литературы. Доктор. Ру. 2015; 13 (114): 73–79.
  76. Reich A., Wróbel G., Kazanowska B. et al. Skin involvement in highly malignant non-Hodgkin lymphomas of childhood and adolescence. Acta Dermatovenerol Alp Pannonica Adriat. 2006; 15 (4): 158–168.
  77. Горенкова Л.Г., Пенская Е.А., Кравченко С.К. и др. Лечение резистентных форм грибовидного микоза и синдрома Сезари. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2017; 10 ( 3): 366–371. DOI: 10.21320/2500-2139-2017-10-3-366-371

Для продолжения работы требуется вход / регистрация